Mobile website
Distribution and pharmacokinetics of recombinant human endostatin in rats
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
To investigate the in vivo pharmacokinetics of recombinant human Endostatin (rhEndostatin) in Wistar rats after i.v. injection, so as to provide pharmacokinetic data for clinical application. Methods:Radioactive isotopic (125I) tracing combined with trichloroacetic acid (TCA) precipitation was used to measure the residual isotope in different tissues at different time points after i.v. injection of 125IrhEndostatin to the rats. Plasma drug concentrationtime data were analyzed by computer fitting. Compartment model and the pharmacokinetic parameters were also established. Results: The distribution halflife time and elimination halflife time of rhEndostatin in rats were (0.154+0.024) h and (4.03+0.58) h, respectively. The AUC were positively correlated with dosages of rhEndostatin (r=0.9940). The mean of CLs value was (0.165±0.024)L/h; the CLs values for high, middle or low dosages were basically the same. The liver, lung, spleen, stomach and thyroid were the major organs for deposition of 125IrhEndostatin. Urinary excretion was the major pathway of elimination. Conclusion: The pharmacokinetics of 125IrhEndostatin in rats basically has a linear character, and the plasma drug concentrationtime curve consists to a twocompartment model.
Keywords:
Project Supported:
Clc Number:
